Condition: Solid Tumor · Sponsor: Biohaven Therapeutics Ltd.
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
This description comes directly from the study's public registry record.
Chief Medical Officer · 203-404-0410 · clinicaltrials@biohavenpharma.com
Always discuss trial participation with your own doctor first.
| Site-113 | Duarte, California, United States | Recruiting |
| Site-112 | La Jolla, California, United States | Recruiting |
| Site-111 | Palo Alto, California, United States | Recruiting |
| Site-114 | Washington D.C., District of Columbia, United States | Recruiting |
| Site-103 | Miami, Florida, United States | Recruiting |
| Site-105 | Orlando, Florida, United States | Recruiting |
| Site-115 | Tampa, Florida, United States | Recruiting |
| Site-110 | Augusta, Georgia, United States | Recruiting |
| Site-109 | Detroit, Michigan, United States | Recruiting |
| Site-101 | St Louis, Missouri, United States | Recruiting |
| Site-117 | New York, New York, United States | Recruiting |
| Site-116 | Oklahoma City, Oklahoma, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06384807